| Description | EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.EIDD-2749 attenuates lethal infections of pandemic human and highly pathogenic avian influenza viruses. |
| In vitro | EIDD-2749（20 uM） 在 HAE 细胞中有效合成代谢，对人气道上皮类器官有效[1]。 |
| In vivo | 在 Balb/cJ 小鼠（RSV 感染模型）中，EIDD-2749（0.2、1、5 mg/kg；口服；每天一次，连续 4 天）能够显著降低肺部病毒载量[1]。 |
| Synonyms | 4'-Fluorouridine, 4'-FlU |
| molecular weight | 262.19 |
| Molecular formula | C9H11FN2O6 |
| CAS | 1613589-24-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 15 mg/mL (57.21 mM), Sonication is recommended. H2O: 50 mg/mL (190.70 mM), Sonication is recommended. |
| References | 1. Sourimant J, et al. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022 Jan 14;375(6577):161-167. 2. Abas AH, et al. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review [version 1; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2022, 11:410. 3. George R. Painter, et al. 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. Patent WO2019173602A1. |